Other · developed by MIRA Pharmaceuticals
Ketamir-2, also called Ketamir hemipamoate, is an oral capsule formulation given in 50 mg or 300 mg doses.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07791303 | Phase 1 | Healthy Adult Participants | Completed | MIRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Adult Participants
Updated Oct 18, 2026. Something wrong or missing? Report it on the MIRA page.
See MIRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MIRA catalysts and pipeline →